Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

SANOFI : PRESS RELEASE : Former Research Chemist At Global Pharmaceutical Company Sentenced To 18 Months In Prison For Theft Of Trade Secrets

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2012 | 07:17pm CEST

United States Attorney

District of New Jersey

FOR IMMEDIATE RELEASE CONTACT: Rebekah Carmichael

May 7, 2012 Office of Public Affairs

www.justice.gov/usao/nj (973) 645-2888

FORMER RESEARCH CHEMIST AT GLOBAL PHARMACEUTICAL COMPANY

SENTENCED TO 18 MONTHS IN PRISON FOR THEFT OF TRADE SECRETS

TRENTON, N.J. - A former research chemist with global pharmaceutical company

sanofi-aventis ("sanofi") was sentenced today to 18 months in prison for stealing sanofi's trade

secrets and making them available for sale through Abby Pharmatech, Inc. ("Abby"), the U.S.

subsidiary of a Chinese chemicals company, U.S. Attorney Paul J. Fishman announced.

Yuan Li, 30, of Somerset, N.J., a Chinese national, previously pleaded guilty to an

Information charging her with one count of theft of trade secrets. Li entered her guilty plea

before U.S. District Judge Joel A. Pisano, who also imposed the sentence today in Trenton

federal court.

According to documents filed in this case and statements made in court:

Sanofi is a global healthcare company with U.S. headquarters in Bridgewater, N.J.

Among other things, sanofi is engaged in the development, manufacture and marketing of

healthcare products including the prescription drugs Allegra, Plavix, Copaxone and Ambien.

Li worked as a research scientist at sanofi's Bridgewater headquarters from October 2006

through June 2011, where she directly assisted in the development of a number of compounds

that sanofi viewed as potential building blocks for future drugs. These compounds were sanofi's

trade secrets and had not been disclosed outside of sanofi in any manner, including by means of a

patent application.

While employed at sanofi, Li was also a 50 percent partner in Abby, which is engaged in

the sale and distribution of pharmaceuticals.

Li admitted that between January 2010 and June 2011, she accessed an internal sanofi

database and downloaded information related to a number of sanofi compounds, including their

chemical structures, onto her sanofi-issued laptop computer. She also admitted she then

transferred the information to her personal home computer by sending it to her personal e-mail

address or via a USB thumb drive.

Li acknowledged that she made the stolen compounds available for sale on Abby's

website.

In addition to the prison term, Judge Pisano sentenced Li to serve two years of supervised

release and ordered her to pay $131,000 in restitution.

U.S. Attorney Fishman credited special agents of the FBI, under the direction of Special

Agent in Charge Michael B. Ward, with the investigation.

The government is represented by Assistant U.S. Attorney Gurbir S. Grewal of the

Computer Hacking and Intellectual Property Section of the U.S. Attorney's Office Economic

Crimes Unit in Newark.

12-159 ###

Defense counsel: Paul Brickfield Esq., River Edge, N.J.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
06/21SANOFI : completes $3.9bn acquisition of Ablynx
AQ
06/21EVOTEC : and Sanofi sign definitive agreement to combat infectious diseases
AQ
06/21LEXICON PHARMACEUTICALS : to Present New Clinical Data at 78th American Diabetes..
AQ
06/20SANOFI : New study on Dengvaxia ill-effects boosts demand for full refund
AQ
06/20SANOFI : Completes Its Acquisition of Ablynx Following Expiration of Squeeze-Out..
AQ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19SANOFI : Recipharm buys Sanofi CMO site in UK, signs long-term supply deal
AQ
06/19EVOTEC : and Sanofi Sign Definitive Agreement to Combat Infectious Diseases
AQ
06/19SANOFI : Evotec says Sanofi deal makes it anti-infectives powerhouse
AQ
06/19PEUGEOT : Sanofi poaches former PSA finance boss Chasseloup de Chatillon
RE
More news
News from SeekingAlpha
06/19Translate Bio Prepares For $100 Million U.S. IPO 
06/19Merger Arbitrage Mondays - June 18, 2018 
06/19Sanofi transfers infectious disease unit to Evotec 
06/19Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice Presiden.. 
06/16STOCKS TO WATCH : Don't Sleep On Vienna 
Financials (€)
Sales 2018 35 273 M
EBIT 2018 8 334 M
Net income 2018 5 099 M
Debt 2018 15 707 M
Yield 2018 4,42%
P/E ratio 2018 16,43
P/E ratio 2019 15,35
EV / Sales 2018 2,84x
EV / Sales 2019 2,69x
Capitalization 84 521 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 77,0 €
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Ameet Nathwani Executive Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-4.93%97 676
JOHNSON & JOHNSON-12.27%328 751
PFIZER0.00%211 871
NOVARTIS-10.17%188 057
ROCHE HOLDING LTD.-12.19%183 625
MERCK AND COMPANY8.90%164 189